DeMichele, A., Clark, A. S., Shea, E., Bayne, E. J., Sterner, C. J., Rohn, K., Dwyer, S., Pan, T., Nivar, I., Chen, Y., Wileyto, P., Berry, L. R., Deluca, S., Savage, J., Makhlin, I., Pant, D. K., Martin, H., Egunsola, A., Mears, N., Goodspeed, B. L., Chislock, E. M., Graves, J., Wang, J., Shih, N., Belka, G. K., Berry, D., Nayak, A., Feldman, M., & Chodosh, L. A. Targeting dormant tumor cells to prevent recurrent breast cancer: a randomized phase 2 trial
, Nature Medicine : 2025
Clark, A. S., Zhao, F., Klein, P., Montero, A. J., Falkson, C., Krill-Jackson, E., Rowland, K., Sardesai, S., Incorvati, J., Dillon, P., Wolff, A. C., Trauger, R., Heineman, T. C., Coffey, M. C., & Miller, K. D. A Phase II Randomized Study of Paclitaxel Alone or Combined with Pelareorep with or without Avelumab in Metastatic Hormone Receptor-Positive Breast Cancer: The BRACELET-01/PrE0113 Study
, Clinical cancer research: 2025
Jung W, Hubbard RA, Smith AM, Ko K, Huang A, Wang J, Isaacs JM, Zhang L, Liu PP, Chen Z, Shah PD, Mintzer D, Bhattacharya S, Knollman HM, Clark AS, Koropeckyj-Cox D, Messinger M, Wilcox NS, Xia C, Narayan V, Upshaw JN, Armenian SH, Ky B. Risk-guided cardioprotection with carvedilol in patients with breast cancer (CCT guide): a phase 1 randomized clinical trial. , Breast Cancer Res Treat: 2025
Garrido-Castro, C. A., Gorthi, A., Kim S.E., D'Ippolito, A., Nanda, R., Abdou, Y., Clark, A. S., Sacks, R. L., O'Connor, T. P., Sinclair, N., Lo, K.M.S., Desrosiers, J., Lin, N. U., Burstein, H. J., Mittendorf, E.A., Painter, C., Eaton, M. L., Barrett, C., Tayob, N., Tolaney, S.M. Cell-free circulating chromatin profiles enable epigenomic characterization of mechanisms of response and resistance to sacituzumab govitecan in breast cancer , 2025 ASCO Annual Meeting: 2025
Clark AS, Zhao F, Klein P, Montero AJ, Falkson C, Jackson EK, Rowland K, Sardesai S, Incorvati J, Dillon P, Wolff AC, Trauger R, Heineman TC, Coffey MC, Miller KD BRACELET-01/PrE0113: A Phase II Randomized Study of Paclitaxel (Pac), Pac/Pelareorep (Pel) or Pac/Pel/Avelumab in Metastatic Hormone Receptor Positive Breast Cancer , Clinical Cancer Research : 2025
Gitto, S. B., Pantel, A. R., Maxwell, K. N., Pryma, D. A., Farwell, M. D., Liu, F., Cao, Q., O'Brien, S. R., Clark, A. S., Shah, P. D., & McDonald, E. S. FluorThanatrace PET imaging as a biomarker of response to PARP inhibitors in breast cancer , Communications medicine: 2025
Berlin, E., Ko, K., Ma, L., Messing, I., Hollawell, C., Smith, A. M., Taunk, N. K., Narayan, V., Upshaw, J. N., Clark, A. S., Shah, P. D., Knollman, H., Bhattacharya, S., Koropeckyj-Cox, D., Wang, J., Yegya-Raman, N., Han, I. S., Lefebvre, B., Li, T., Wilcox, N. S., Jung, W., Chen, J., Freedman, G. M., Ky, B. Cardiac Effects of Modern Breast Radiation Therapy in Patients Receiving Systemic Cancer Therapy
, JACC. CardioOncology: 2025
Linden HM, Ewen D, Mankoff D, Dehdashti F, Fowler AM, Clark AS, Specht JM, Peterson LM [18F]Fluoroestradiol (FES)-PET as a predictive measure for endocrine therapy in patients with newly diagnosed metastatic breast cancer: Results from EAI142 , San Antonio Texas Breast Cancer Symposium, San Antonio, TX: 2024
Puhalla SL, Tang G, Swain SM, Ganz PA, Lynn Henry NL, Cecchini RS, Reid SA, Rastogi P, Geyer CE, White JR, Clark AS, Haddad TC, Vidal GA, Wolmark N, Mamounas EP NRG-BR009: Phase III Trial Evaluating Addition of Adjuvant Chemotherapy to Ovarian Function Suppression + Endocrine Therapy in Premenopausal Women with pN0-1, HR+/HER2- Breast Cancer and Oncotype Recurrence Score ≤25 (OFSET) , San Antonio Breast Cancer Symposium, San Antonio, TX.: 2024
Garrido-Castro AC, Desrosiers JA, Nanda R, Abdou YG, Clark AS, Sacks RL, O'Connor TP, Sinclair NF, Lo S, Thomas A, Wrabel E, DiLullo MK, Patel A, Rahman T, O'Meara TA, Keenan T, Dillon, DA, Lin NU, Burstein HJ, Mittendorf EA, Junkins KE, Rahee HA Correlation of TROP2 expression with outcomes of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer: an exploratory analysis from the phase II SACI-IO HR+ trial , San Antonio Breast Cancer Symposium, San Antonio, TX: 2024
